{
    "clinical_study": {
        "@rank": "147923", 
        "acronym": "ANTHEM-HF", 
        "arm_group": [
            {
                "arm_group_label": "Left Sided Stimulation", 
                "arm_group_type": "Experimental", 
                "description": "Left cervical Vagus Nerve Stimulation (VNS)"
            }, 
            {
                "arm_group_label": "Right Sided Stimulation", 
                "arm_group_type": "Experimental", 
                "description": "Right Cervical Vagus Nerve Stimulation (VNS)"
            }
        ], 
        "brief_summary": {
            "textblock": "The ANTHEM-HF Study is designed to demonstrate the safety and efficacy of vagus nerve\n      stimulation (VNS) with the Cyberonics VNS Therapy System for the treatment of subjects with\n      symptomatic heart failure."
        }, 
        "brief_title": "Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Congestive Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "Heart failure patients will be enrolled and randomized to cervical VNS implantation on\n      either the left side or right side. After a 2-week post-implantation recovery period and a\n      10-week stimulation titration period, continuous periodic stimulation will be performed for\n      6 months, with data collection at 3 months and 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with symptomatic heart failure, New York Heart Association (NYHA) class\n             II/III with reduced EF and dilated hearts"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823887", 
            "org_study_id": "C-01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Left Sided Stimulation", 
                "Right Sided Stimulation"
            ], 
            "description": "Electrical Stimulation of the Vagus Nerve", 
            "intervention_name": "Vagus Nerve Stimulation (VNS)", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Heart Failure", 
            "Vagus Nerve", 
            "VNS"
        ], 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chennai", 
                    "country": "India"
                }
            }
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study", 
        "overall_official": {
            "affiliation": "Cyberonics, Inc.", 
            "last_name": "Imad Libbus, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "India: Drugs Controller General of India", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Left ventricular end-systolic volume (LVESV), left ventricular end-systolic diameter (LVESD), and ejection fraction (EF)", 
                "measure": "Cardiac Function", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Incidence of procedure and device-related complications", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823887"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "6-minute walk test", 
                "measure": "Functional Status", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Minnesota Living with Heart Failure Questionnaire", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "New York Heart Association Class", 
                "measure": "Functional Status", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Heart Rate Variability (HRV)", 
                "measure": "Autonomic Function", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Blood Levels of Heart Failure Biomarkers", 
                "measure": "Blood Biomarkers", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Cyberonics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cyberonics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}